Drugs / Carboxylesterase-expressing Allogeneic Neural Stem Cells
Carboxylesterase-expressing Allogeneic Neural Stem Cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02192359 | Apr 2016 → Feb 2022 overdue | anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma, gliosarcoma | City of Hope Medical Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02055196 | ? → May 2014 | adult glioblastoma, anaplastic astrocytoma, anaplastic oligodendroglioma, giant cell glioblastoma +1 | City of Hope Medical Center | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | carboxylesterase-expressing allogeneic neural stem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02055196 ↗ |
| Modality | Cell therapy | “carboxylesterase-expressing allogeneic neural stem cells” NCT02055196 ↗ |
| Route | Other | “via intracerebral catheter” NCT02055196 ↗ |